ArticleFrontiers in molecular biosciences2023
Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Membrane-Anchored Serine Protease Inhibitors: Physiological Functions, Mechanisms, and Roles in Cancer.International journal of molecular sciences · 2026Review
- Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin.International journal of molecular sciences · 2026Review
- Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 2 countries.
Maria Carmen RodenasDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Julia Peñas-MartínezDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Irene Pardo-SánchezDepartment of Cell Biology, Faculty of Biology, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
David Zaragoza-HuescaDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Carmen Ortega-SabaterDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Jorge Peña-GarcíaComputer Engineering Department, Structural Bioinformatics and High Performance Computing Research Group (BIO-HPC), UCAM Universidad Católica de Murcia, Guadalupe, Spain.
Salvador EspínDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Guillermo RicoteDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Sofía MontenegroDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Francisco Ayala-De La PeñaDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Ginés Luengo-GilClinical Analysis and Pathology Department, Group of Molecular Pathology and Pharmacogenetics, IMIB-Pascual Parrilla, Hospital Universitario Santa Lucía, Cartagena, Spain.
Andrés NietoDepartment of Pathology, Hospital Universitario Morales Meseguer, Murcia, Spain.
Francisco García-MolinaDepartment of Pathology, Hospital Universitario Reina Sofía, Murcia, Spain.
Vicente VicenteDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Francesco BernardiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
María Luisa LozanoDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Victoriano MuleroDepartment of Cell Biology, Faculty of Biology, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Horacio Pérez-SánchezComputer Engineering Department, Structural Bioinformatics and High Performance Computing Research Group (BIO-HPC), UCAM Universidad Católica de Murcia, Guadalupe, Spain.
Alberto Carmona-BayonasDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Irene Martínez-MartínezDepartment of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Centro de Investigación Biomédica en Red de Enfermedades Raras, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
Universidad de Murcia · ESCentro Regional de Hemodonación · ESUniversidad Católica San Antonio de Murcia · ESCentre for Biomedical Network Research on Rare Diseases · ESHospital General Universitario Morales Meseguer · ESHospital Universitario Reina Sofía · ESSanta Lucía University General Hospital · ESUniversity of Ferrara · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
colorectal cancerhepsinmetastasismolecular-targeted therapythrombosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.